FOXP3 and neoplasm: To corroborate the above in silico immunophenotyping, we next profiled the immune infiltrate of subcutaneous tumours derived from IFNγ-naïve YUMM2.1 cells expressing shNTC or chronic IFNγ pre-treated YUMM2.1 cells expressing either shNTC or shPARP14 (Fig. 5F) by flow cytometry using fluorescent labelling for a panel of T cell markers including TCRαβ, TCRγδ, CD45, CD25, and FoxP3 (Supplementary Fig. 9A for gating strategy).